These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Milanese C; La Mantia L; Salmaggi A; Campi A; Eoli M; Scaioli V; Nespolo A; Corridori F Eur Neurol; 1989; 29(1):10-4. PubMed ID: 2540005 [TBL] [Abstract][Full Text] [Related]
6. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. Tremlett HL; Luscombe DK; Wiles CM J Neurol Neurosurg Psychiatry; 1998 Sep; 65(3):362-5. PubMed ID: 9728950 [TBL] [Abstract][Full Text] [Related]
10. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression]. Wender M; Tokarz-Kupczyk E; Mularek O Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379 [TBL] [Abstract][Full Text] [Related]
11. [Corticoids and multiple sclerosis]. Defer G; Cesaro P; Degos JD Ann Med Interne (Paris); 1994 Jun; 145 Suppl 2():37-41. PubMed ID: 8074340 [No Abstract] [Full Text] [Related]
12. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Uttner I; Müller S; Zinser C; Maier M; Süssmuth S; Claus A; Ostermann B; Elitok E; Ecker D; Brettschneider J; Gold R; Tumani H Neurology; 2005 Jun; 64(11):1971-3. PubMed ID: 15955958 [TBL] [Abstract][Full Text] [Related]
13. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH]. Wender M; Tokarz-Kupczyk E; Mularek O Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886 [TBL] [Abstract][Full Text] [Related]
14. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063 [TBL] [Abstract][Full Text] [Related]
15. Adrenocorticotrophic potency of long-acting corticotrophin preparations during long-term treatment of neurological patients. Rinne UK Ann Med Intern Fenn; 1968; 57(4):167-72. PubMed ID: 4307479 [No Abstract] [Full Text] [Related]
16. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Durelli L; Cocito D; Riccio A; Barile C; Bergamasco B; Baggio GF; Perla F; Delsedime M; Gusmaroli G; Bergamini L Neurology; 1986 Feb; 36(2):238-43. PubMed ID: 3511404 [TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
18. A critical evaluation and review of ACTH (corticotrophin) in the treatment of acute exacerbations of multiple sclerosis. Blustein H; Wasserman RR; Halperin L; Garvin JS Med Times; 1969 Dec; 97(12):137-41. PubMed ID: 4312534 [No Abstract] [Full Text] [Related]
19. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. Alam SM; Kyriakides T; Lawden M; Newman PK J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1219-20. PubMed ID: 8229035 [TBL] [Abstract][Full Text] [Related]
20. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. Lyons PR; Newman PK; Saunders M J Neurol Neurosurg Psychiatry; 1988 Feb; 51(2):285-7. PubMed ID: 3346696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]